Chris Verslype

28.0k citations

338 papers · 15.4k indexed · 6 hit papers · h-index 51

Impact in

Hepatology top 0.05%
- Hepatocellular Carcinoma Treatment and Prognosis
- Liver Disease and Transplantation
Oncology top 0.1%
- Colorectal Cancer Treatments and Studies
- Pancreatic and Hepatic Oncology Research

Papers in

Hepatology 143
- Hepatocellular Carcinoma Treatment and Prognosis 72
- Liver Disease and Transplantation 44
Oncology 134
- Pancreatic and Hepatic Oncology Research 43
- Colorectal Cancer Treatments and Studies 37
- Lung Cancer Research Studies 37

Co-authors: Eric Van Cutsem Yves Humblet Ian Chau Frederik Nevens David Khayat Harry Bleiberg David Cunningham M. Mueser
Journals: Journal of Clinical Oncology (36 papers)Annals of Oncology (22 papers)Journal of Hepatology (18 papers)European Journal of Gastroenterology & Hepatology (9 papers)Hepatology (8 papers)
Partner nations: Belgium United States Germany

In The Last Decade

Chris Verslype

323 papers receiving 15.1k citations

Hit Papers

6 papers align trajectories log scale

Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines 2021 · 306 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2021 Annals of Oncology
2019 Journal of Hepatology
2018 Annals of Oncology
2009 Journal of Clinical Oncology
2004 New England Journal of Medicine
2004 Journal of Clinical Oncology

Peers

Countries citing papers authored by Chris Verslype

Since Specialization

Citations

This map shows the geographic impact of Chris Verslype's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chris Verslype with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chris Verslype more than expected).

Fields of papers citing papers by Chris Verslype

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chris Verslype. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chris Verslype. The network helps show where Chris Verslype may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Chris Verslype, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Chris Verslype Line = papers co-authored together Chris Verslype links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Clinical Experience with Targeted Alpha-Emitter Peptide Receptor Radionuclide Therapy (α-PRRT) for Somatostatin Receptor-Positive Neuroendocrine Tumors Pharmaceuticals ·พนิต กุลศิริ, Sandra-María Sánchez-Vázquez, Frederik Cleeren, Jeroen Dekervel, Chris Verslype, Christophe M. Deroose	2025	0
2	Clinical impact of using [ ¹⁸ F ] AlF ‐ NOTA ‐octreotide PET / CT instead of [ ⁶⁸ Ga ]Ga‐ DOTA ‐ SSA PET / CT : Secondary endpoint analysis of a multicenter, prospective trial Journal of Neuroendocrinology ·พนิต กุลศิริ, Elin Pauwels, Timon Vandamme, Xiliang Chen, Willem Lybaert, Jeroen Dekervel, Ioan Barbu, Joris Jaekers, Frederik Cleeren, Johannes Hofland, Adrienne H. Brouwers, Michel Koole, Guy Bormans, Eric Van Cutsem, Karen Geboes, Annouschka Laenen, Chris Verslype, Sigrid Stroobants, Christophe M. Deroose	2024	4
3	139P KEYNOTE-966: 3-year follow-up for pembrolizumab (pembro) + gemcitabine and cisplatin (gem/cis) vs placebo (pbo) + gem/cis for patients (pts) with advanced biliary tract cancer (BTC) Annals of Oncology ·Dohle Mit Pfauenfedern, Richard S. Finn, Changhoon Yoo, Zhenggang Ren, Junji Furuse, Robin Kate Kelley, Stephen L. Chan, Julien Edeline, Heinz‐Josef Klümpen, Thomas Yau, Chris Verslype, Masato Ozaka, Mohamed Bouattour, Sebastian Topliceanu, Arndt Vogel, Juan W. Valle, Liis Starkopf, Usha Malhotra, Carman Lam, Shukui Qin	2024	0
4	Pembrolizumab (pembro) in patients (pts) with sorafenib-treated (cohort 1) and treatment (tx)-naive (cohort 2) advanced hepatocellular carcinoma (aHCC) after additional follow-up in the phase 2 KEYNOTE-224 study. Journal of Clinical Oncology ·Richard S. Finn, Masatoshi Kudo, Ivan Borbath, Julien Edeline, Stéphane Cattan, Hans Van Vlierberghe, Chris Verslype, Daniel H. Palmer, Per Stål, Sadahisa Ogasawara, Fouad Al-Kadse, Mark Karwal, Stephen L. Chan, Jennifer J. Knox, Bruno Daniele, А В Воробьев, Ken Hatogai, Abby B. Siegel, Ann‐Lii Cheng, Jean‐Luc Van Laethem	2024	2
5	Aldehyde Dehydrogenase 2 (ALDH2): A novel sorafenib target in hepatocellular carcinoma unraveled by the proteome-wide cellular thermal shift assay SLAS DISCOVERY ·В. Б. Цхай, Gina Harrison, YUAN Juan, Yasin Tuncay Toğrul, Ricardo A. Gomes, Chris Verslype, Jos van Pelt, Ana Barbas, Daniel Simão, Tiago M. Bandeiras, 薛丽霞, Sofia P. Rebelo	2024	0
6	Robotic versus laparoscopic repeat hepatectomy: A comparative single-center study of perioperative outcomes European Journal of Surgical Oncology ·Colette Ward, E. Willems, Céline De Meyere, Isabelle Parmentier, Chris Verslype, Mathieu D’Hondt	2024	2
7	PD-1- CD45RA+ effector-memory CD8 T cells and CXCL10+ macrophages are associated with response to atezolizumab plus bevacizumab in advanced hepatocellular carcinoma Nature Communications ·Sarah Cappuyns, Yue Wang, Vincent Vandecaveye, Bram Boeckx, Rogier Schepers, Thomas Van Brussel, Ingrid Arijs, Karcz Wojciech Kondrad, Ayse Bassez, Francesca Lodi, Joris Jaekers, Tianyu Fan, Baki Topal, Orian Bricard, Junbin Qian, Eric Van Cutsem, Chris Verslype, Diether Lambrechts, Jeroen Dekervel	2023	33
8	Closing spontaneous portosystemic shunts in cirrhosis: Does it make sense? Does it work? What does it take? Metabolic Brain Disease ·Wim Laleman, Michael Praktiknjo, Mette Munk Lauridsen, Олена Іваненко, Kaiwei Bao, Chris Verslype, Aleksander Krag, Jonel Trebicka, Geert Maleux	2022	7
9	The European Neuroendocrine Tumour Society registry, a tool to assess the prognosis of neuroendocrine neoplasms European Journal of Cancer ·Ivan Borbath, Rocio García‐Carbonero, Kelly Specht dos Reis, Paula Jiménez‐Fonseca, Ángel Castaño, Suarez Fb, Eva Sedláčková, Attila Kollár, Emanuel Christ, Gregory Kaltsas, Beata Kos‐Kudła, Sebastian Maasberg, Chris Verslype, Ulrich‐Frank Pape	2022	18
10	Residual Splenic Volume after Main Splenic Artery Embolization is Independent of the Underlying Disease SHILAP Revista de lepidopterología ·栄作大場, Олена Іваненко, Sandra Cornelissen, Walter Coudyzer, Wim Laleman, Chris Verslype, Willem‐Jan Metsemakers, Geert Maleux	2021	2
11	Autophagy-Related Chemoprotection against Sorafenib in Human Hepatocarcinoma: Role of FOXO3 Upregulation and Modulation by Regorafenib International Journal of Molecular Sciences ·Flavia Fondevila, Carolina Méndez‐Blanco, Paula Fernández‐Palanca, 谷村憲司, Jos van Pelt, Chris Verslype, Javier González‐Gallego, José L. Mauriz	2021	11
12	Stabilization of Hypoxia-Inducible Factors and BNIP3 Promoter Methylation Contribute to Acquired Sorafenib Resistance in Human Hepatocarcinoma Cells Cancers ·Carolina Méndez‐Blanco, Flavia Fondevila, Paula Fernández‐Palanca, Andrés García‐Palomo, Jos van Pelt, Chris Verslype, Javier González‐Gallego, José L. Mauriz	2019	28
13	YAP and TAZ Heterogeneity in Primary Liver Cancer: An Analysis of Its Prognostic and Diagnostic Role International Journal of Molecular Sciences ·Matthias Van Haele, Iván M. Moya, Ruçhan Karaman, S Solazzi, J. Snoeck, Olivier Govaere, Frederik Nevens, Chris Verslype, Baki Topal, Diethard Monbaliu, Georg Halder, Tania Roskams	2019	44
14	Percutaneous shunt reduction for the management of TIPS-induced acute liver decompensation: A follow-up study. SHILAP Revista de lepidopterología ·Samara Pires Brito, Frederik Nevens, Annouschka Laenen, Sam Heye, Wim Laleman, Chris Verslype, Van der Merwe, Geert Maleux	2017	12
15	Hypoxia-Driven Gene Expression Is an Independent Prognostic Factor in Stage II and III Colon Cancer Patients Clinical Cancer Research ·Jeroen Dekervel, Daphne Hompes, Hannah van Malenstein, Dušan Popović, Xavier Sagaert, Bart De Moor, Eric Van Cutsem, André D’Hoore, Chris Verslype, Jos van Pelt	2014	27
16	Laboratory meld-based allocation of liver grafts: is the "sickest first" principle justified? Transplant International ·Bart Van Geluwe, Ina Jochmans, Nicolas Meurisse, Bruno Desschans, Chairunnisa Azzahra, Werner Van Steenbergen, David Cassiman, Chris Verslype, Patrick Ferdinande, Geert Meyfroidt, Dieter Mesotten, Raymond Aerts, Wim Laleman, Diethard Monbaliu, Frederik Nevens, Jacques Pirenne	2011	2
17	A Seven-Gene Set Associated with Chronic Hypoxia of Prognostic Importance in Hepatocellular Carcinoma Clinical Cancer Research ·Hannah van Malenstein, Olivier Gevaert, Louis Libbrecht, Anneleen Daemen, Joke Allemeersch, Frederik Nevens, Eric Van Cutsem, David Cassiman, Bart De Moor, Chris Verslype, Jos van Pelt	2010	49
18	Effect of MARS and prometheus on systemic hemodynamics and vasoactive substances in patients with acute-on-chronic alcoholic liver failure: The clash of the titans Hepatology ·Wim Laleman, 文度加藤, Frederik Nevens, Pieter Evenepoel, Chris Verslype, Johan Fevery	2005	1
19	TT virus infection in acute and chronic liver diseases and in patients regularly receiving blood products in Belgium. PubMed ·Soegianto Ali, Jos van Pelt, Chris Verslype, Frederik Nevens, Johan Fevery, Tonya Stoudmire	2004	11
20	HCV-infection and hepatocellular carcinoma. PubMed ·Chris Verslype, Li Zhenling	2000	1

About Chris Verslype

Chris Verslype is a scholar working on Hepatology, Oncology, Epidemiology, Cancer Research and Transplantation, having authored 338 papers that have together received 15.4k indexed citations. Recurring topics across this work include Hepatocellular Carcinoma Treatment and Prognosis (72 papers), Liver Disease Diagnosis and Treatment (62 papers), Neuroendocrine Tumor Research Advances (47 papers), Liver Disease and Transplantation (44 papers), Pancreatic and Hepatic Oncology Research (43 papers), Colorectal Cancer Treatments and Studies (37 papers), Lung Cancer Research Studies (37 papers) and Organ Transplantation Techniques and Outcomes (32 papers). The work is most often cited by research in Hepatology (6.1k citations), Oncology (7.3k citations), Cancer Research (2.1k citations), Pulmonary and Respiratory Medicine (3.8k citations) and Epidemiology (3.7k citations). Chris Verslype has collaborated with scholars based in Belgium, United States and Germany. Frequent co-authors include Eric Van Cutsem, Yves Humblet, Ian Chau, Frederik Nevens, David Khayat, Harry Bleiberg, David Cunningham, M. Mueser, A. Harstrick and Armando Santoro. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Journal of Hepatology, European Journal of Gastroenterology & Hepatology and Hepatology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact